Abstract:HIV-ITP patients have a unique Ab against platelet GPIIIa49-66 which induces oxidative platelet fragmentation in the absence of complement (Cell 106: 551, 2001; JCI 113: 973, 2004). Since HCV-ITP, like HIV-ITP, is associated with circulating immune complexes, we asked whether the complexes could contain platelet fragments induced by oxidative platelet fragmentation and whether HCV-ITP could be induced by molecular mimickry with an HCV peptide. The incidence of Hepatitis-C related ITP varies from 10–40% increasing with severity of liver disease. HIV-ITP is more frequent in drug abusers compared to non-drug abusers (37% vs 16%); and more severe in HIV-drug abusers than non-drug abusers (platelets <10,000/ul in 52% vs 9%). A striking feature of HIV-infection in drug abusers is the frequent co-infection with HCV. HCV infection in non-drug abusers (~30%) increase to 90% in drug abusers. We asked whether coinfection with HCV facilitates ITP, and if so, which would be the mechanism. We screened a 7 mer peptide phage library with anti-GPIIIa49-66 Ab as bait for peptides showing homology sequences with HCV protein. Three clones had 70% homology with HCV protein, as well as a non-conserved core envelope 1 peptide, PHC09 (SAIHIRNASG). Three additional non-conserved envelope 1 peptides with 70% homology for PHC09 were found in the NIH data base (PHC09-H4, PHC09-H5 and PHC09-H6). The envelope 1 protein is a known neutralizing HCV epitope reactive with human MoAb vs 12 different HCV Envelope 1 isolates, containing the candidate linear epitope _ _ RN_SG_Y_. Sera from dually infected thrombocytopenic patients with HCV and HIV-ITP reacted strongly with PHC09 and correlated inversely with platelet count r2=0.7, p<0.01, n=15. Ab raised against this peptide in GPIIIa −/− mice induced severe thrombocytopenia in wild-type mice, n=4. Affinity-purified IgG against PHC09 induced oxidative platelet fragmentation in vitro, n=5. Drug abusers dually infected with HCV and HIV had a greater incidence and severity of thrombocytopenia (<30,000/ul) in 8/15 dually infected patients compared to 2/15 HCV-ITP (p<0.025) or 3/15 HIV-ITP patients (p=0.06). This was associated with a greater incidence and titer of anti-GPIIIa49-66 Ab in 12/15 HCV-HIV-ITP compared to 2/15 HCV-ITP (P=0.001) or 6/15 HIV-ITP patients (p<0.05). They also had a greater incidence of anti PHC09 Ab in 10/15 HCV-HIV-ITP patients compared to 3/15 HCV-ITP (p=0.004) or 1/15 HIV-ITP patients (p=0.001). Similar findings were obtained with PHC09-H5. NZB/W F1 mice injected with recombinant core envelope 1 developed Ab titers vs PHC09 and significantly lowered their platelet count by 60%, compared to controls, P<0.001. Anti-PHC09 Ab correlated inversely with platelet count, r2=0.63, n=15, P<0.05, n=8. Thus, 1) HCV-ITP complexes contain anti-PHC09 Ab capable of inducing oxidative platelet fragmentation; 2) HCV-ITP can be induced by molecular mimickry with HCV core envelope 1 protein, PHC09; 3) Dually infected ITP drug abusers with HIV and HCV have greater titers of anti-GPIIIa49-66/PHC09 Ab than HCV-ITP or HIV-ITP patients and more severe thrombocytopenia.

Integrin GPIIIa49-57 is the pivotal switch controlling platelet fragmentation.

Platelet Fragmentation Requires a Specific Structural Conformation of Human Monoclonal Antibody against β3 Integrin

Synergistic Effects of Bifunctional Antibodies Against Beta3 Integrin on Dissolution of Platelet Thrombus,

A critical role for the regulation of Syk from agglutination to aggregation in human platelets

Identification of human platelet specific functional antibody and its fragments

A humanized single-chain variable fragment antibody against beta3 integrin in Escherichia coli.

Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus

Effects of IgG and its F(ab')2 fragments of some patients with idiopathic thrombocytopenic purpura on platelet aggregation.

Fc-independent Immune Thrombocytopenia Via Mechanomolecular Signaling in Platelets.

Abstract 383: Paired Immunoglobin-Like Receptor B Regulates Platelet Activation

Akt-mediated Platelet Apoptosis and Its Therapeutic Implications in Immune Thrombocytopenia.

C-terminal ADAMTS-18 Fragment Induces Oxidative Platelet Fragmentation, Dissolves Platelet Aggregates, and Protects Against Carotid Artery Occlusion and Cerebral Stroke

The Immunoreactivity of IgG and Its Fragments from ITP Patients and Their Effects on Platelet Aggregation Function

Platelet Desialylation: A Novel Mechanism of Fc-Independent Platelet Clearance and A Potential Diagnostic Biomarker and Therapeutic Target in Immune Thrombocytopenia

The Role of Mitochondrial Permeability Transition Pore in Regulating the Shedding of the Platelet GPIbα Ectodomain.

The effects of complement-independent, autoantibody-induced apoptosis of platelets in immune thrombocytopenia (ITP)

Role of Molecular Mimickry of Hepatitis C Virus (HCV) Protein with Platelet GPIIIa in Hepatitis C-Related Immunologic Thrombocytopenia

Essential role of glycoprotein Ibα in platelet activation

An Unexpected Role for Αiibβ3 in Immune Complex Disorders

Interspecies Comparison of Platelet Aggregation, LIBS Expression and Clot Retraction: Observed Differences in GPIIb-IIIa Functional Activity

Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized-murine model of ITP